Several other analysts have also issued reports on AZN. JPMorgan Chase & Co. set a GBX 5,800 ($75.79) target price on AstraZeneca and gave the company a buy rating in a research note on Monday, July 9th. Barclays reiterated an overweight rating and issued a GBX 6,500 ($84.93) price target (up from GBX 6,300 ($82.32)) on shares of AstraZeneca in a research report on Tuesday, July 10th. Jefferies Financial Group lifted their price target on AstraZeneca from GBX 6,000 ($78.40) to GBX 6,050 ($79.05) and gave the company a buy rating in a research report on Friday, July 13th. Deutsche Bank reiterated a buy rating and issued a GBX 6,000 ($78.40) price target (up from GBX 5,700 ($74.48)) on shares of AstraZeneca in a research report on Friday, July 13th. Finally, Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research report on Thursday, July 26th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of GBX 5,793 ($75.70).
Shares of AZN opened at GBX 5,822 ($76.07) on Tuesday. AstraZeneca has a 1 year low of GBX 4,260 ($55.66) and a 1 year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Float
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.